A Retrospective Evaluation of Phenobarbital and Benzodiazepine Monotherapy and Combined Therapy in the Treatment of Alcohol Withdrawal Syndrome in a Canadian Emergency Department
Abstract
Purpose The first-line treatment for alcohol withdrawal syndrome (AWS) in the emergency department (ED) is benzodiazepines. Phenobarbital is used as an alternative first-line treatment for AWS in admitted patients. This retrospective cohort study assessed the safety and efficacy of phenobarbital and benzodiazepines as first-line treatments of AWS in a Canadian ED. Methods A retrospective chart review was performed of patients seen at a Canadian tertiary care ED from January 2022 until December 2023. Patients were included if they were treated in the ED for AWS with phenobarbital or benzodiazepines, either as monotherapy or as combined therapy. The primary outcome was the time from medication administration to disposition (discharge or admission). Secondary outcomes included ED length of stay, time to medication administration, admission rates, 48-hour ED return visits, and adverse events. Statistical comparisons were performed using ANOVA and chi-square testing with post hoc analyses. Results A total of 342 patient encounters were included. The majority of patients (n = 203) were treated with benzodiazepine monotherapy, and 97 patients were treated with phenobarbital monotherapy. There was no significant difference in the primary outcome between the phenobarbital and benzodiazepine monotherapy groups. Combined use of phenobarbital and benzodiazepines was associated with a longer time to disposition, potentially reflecting patients with more severe symptoms or…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 203 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.